First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.
Antonio Nieto GarcíaÁngel Mazón RamosMaría NietoEthel IbáñezDah Tay JangSusana CalaforraPilar AlbaCarmen Pérez-FrancésRuth LlusarJavier MontoroAntonio de MateoRemedios AlamarDavid El-QutobFrancisco Javier Fernández SánchezLuis MoralTeresa ToralMónica AntónCarmen AndreuÁngel FerrerIsabel-María FloresNeus CerdáSandra Del PozoRaquel CaballeroJosé Luis SubizaMiguel CasanovasPublished in: Allergy (2022)
PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.